DI Leu16 IL-2 / Provenance, Alopexx, Shenogen Pharma, EMD Serono - LARVOL DELTA

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL (clinicaltrials.gov) - P1/2; N=5; Terminated; Sponsor: Alopexx Oncology, LLC; Completed ➔ Terminated; Clinical benefit was noted before the scheduled completion of the trial and the extension study was terminated early.

Clinical • Trial termination • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • IL2

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (clinicaltrials.gov) - P1/2; N=24; Terminated; Sponsor: Alopexx Oncology, LLC; Completed ➔ Terminated; Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.

Clinical • Trial termination • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL (clinicaltrials.gov) - P1/2; N=24; Completed; Sponsor: Alopexx Oncology, LLC; Recruiting ➔ Completed; N=66 ➔ 24; Trial primary completion date: Dec 2016 ➔ Sep 2016

Enrollment change • Trial completion • Trial primary completion date • Biosimilar • Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

Alopexx Oncology announces licensing agreement with Beijing Shenogen Pharma Group for development and commercialization of novel immunocytokine for the treatment of B-cell lymphomas in China/Asia (PRNewswire) - "Alopexx Oncology, LLC announced today that it has entered into an exclusive license agreement with Beijing Shenogen Pharma Group to develop and commercialize DI-Leu16-IL2 in China and other parts of Asia. Alopexx will receive an upfront payment, various development and commercial milestones and royalties on sales."

Licensing / partnership